On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) opened lower -0.31% from the last session, before settling in for the closing price of $70.13. Price fluctuations for BMRN have ranged from $67.75 to $99.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.23% over the last five years. Company’s average yearly earnings per share was noted 131.06% at the time writing. With a float of $187.97 million, this company’s outstanding shares have now reached $188.60 million.
The firm has a total of 3401 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.37%, operating margin of 8.59%, and the pretax margin is 11.53%.
Biomarin Pharmaceutical Inc. (BMRN) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Biomarin Pharmaceutical Inc. is 1.27%, while institutional ownership is 99.70%. The most recent insider transaction that took place on Aug 13 ’24, was worth 64,260. In this transaction GVP, Chief Accounting Officer of this company sold 714 shares at a rate of $90.00, taking the stock ownership to the 14,449 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Officer proposed sale 714 for $90.00, making the entire transaction worth $64,260.
Biomarin Pharmaceutical Inc. (BMRN) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0.21 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at 0.23) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 131.06% per share during the next fiscal year.
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Trading Performance Indicators
Check out the current performance indicators for Biomarin Pharmaceutical Inc. (BMRN). In the past quarter, the stock posted a quick ratio of 1.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.14. Likewise, its price to free cash flow for the trailing twelve months is 57.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.32, a number that is poised to hit 0.58 in the next quarter and is forecasted to reach 3.13 in one year’s time.
Technical Analysis of Biomarin Pharmaceutical Inc. (BMRN)
Analysing the last 5-days average volume posted by the [Biomarin Pharmaceutical Inc., BMRN], we can find that recorded value of 1.42 million was lower than the volume posted last year of 1.84 million. As of the previous 9 days, the stock’s Stochastic %D was 38.54%. Additionally, its Average True Range was 1.43.
During the past 100 days, Biomarin Pharmaceutical Inc.’s (BMRN) raw stochastic average was set at 7.97%, which indicates a significant decrease from 47.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 9.53% in the past 14 days, which was lower than the 39.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $76.65, while its 200-day Moving Average is $83.26. Now, the first resistance to watch is $70.58. This is followed by the second major resistance level at $71.25. The third major resistance level sits at $71.94. If the price goes on to break the first support level at $69.22, it is likely to go to the next support level at $68.53. Now, if the price goes above the second support level, the third support stands at $67.86.
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Key Stats
There are currently 189,880K shares outstanding in the company with a market cap of 13.31 billion. Presently, the company’s annual sales total 2,419 M according to its annual income of 167,650 K. Last quarter, the company’s sales amounted to 712,030 K and its income totaled 107,170 K.
